Both LDL and HDL particle concentrations associate positively with an increased risk of developing microvascular complications in patients with type 2 diabetes: lost protection by HDL (Zodiac-63).


Journal

Cardiovascular diabetology
ISSN: 1475-2840
Titre abrégé: Cardiovasc Diabetol
Pays: England
ID NLM: 101147637

Informations de publication

Date de publication:
06 07 2023
Historique:
received: 31 05 2023
accepted: 30 06 2023
medline: 10 7 2023
pubmed: 7 7 2023
entrez: 6 7 2023
Statut: epublish

Résumé

Triglyceride-rich lipoproteins (TRL) and low-density lipoproteins (LDL) are associated positively whereas high-density lipoproteins (HDL) are associated inversely with the development of new-onset type 2 diabetes (T2D). Here we studied potential associations between these lipoprotein particle concentrations and the risk of developing microvascular complications in patients with established T2D. Lipoprotein particle concentrations (TRLP, LDLP, and HDLP) were determined in 278 patients with T2D participating in a primary care-based longitudinal cohort study (Zwolle Outpatient Diabetes project Integrating Available Care [ZODIAC] study) leveraging the Vantera nuclear magnetic resonance (NMR) platform using the LP4 algorithm. Associations between lipoprotein particles and incident microvascular complications (nephropathy, neuropathy, and retinopathy) were assessed using Cox proportional hazards regression models. In total, 136 patients had microvascular complications at baseline. During a median follow-up of 3.2 years, 49 (34.5%) of 142 patients without microvascular complications at baseline developed new-onset microvascular complications. In multivariable Cox proportional hazards regression analyses, both total LDLP and HDLP concentrations, but not total TRLP concentrations, were positively associated with an increased risk of developing any microvascular complications after adjustment for potential confounding factors, including age, sex, disease duration, HbA1c levels, history of macrovascular complications, and statin use (adjusted hazard ratio [HR] per 1 SD increment: 1.70 [95% CI 1.24-2.34], P < 0.001 and 1.63 [95% CI 1.19-2.23], P = 0.002, respectively). When analyzing each microvascular complication individually, total LDLP concentrations were positively associated with retinopathy (adjusted HR 3.35, 95% CI 1.35-8.30, P = 0.009) and nephropathy (adjusted HR 2.13, 95% CI 1.27-3.35, P = 0.004), and total HDLP concentrations with neuropathy (adjusted HR 1.77, 95% CI 1.15-2.70, P = 0.009). No significant associations were observed for lipoprotein particle subfractions. Total lipoprotein particle concentrations of both LDL and HDL associate positively with an increased risk of developing microvascular complications in T2D. We propose that the protective role of HDL on the development of microvascular complications may be lost in established T2D.

Sections du résumé

BACKGROUND
Triglyceride-rich lipoproteins (TRL) and low-density lipoproteins (LDL) are associated positively whereas high-density lipoproteins (HDL) are associated inversely with the development of new-onset type 2 diabetes (T2D). Here we studied potential associations between these lipoprotein particle concentrations and the risk of developing microvascular complications in patients with established T2D.
METHODS
Lipoprotein particle concentrations (TRLP, LDLP, and HDLP) were determined in 278 patients with T2D participating in a primary care-based longitudinal cohort study (Zwolle Outpatient Diabetes project Integrating Available Care [ZODIAC] study) leveraging the Vantera nuclear magnetic resonance (NMR) platform using the LP4 algorithm. Associations between lipoprotein particles and incident microvascular complications (nephropathy, neuropathy, and retinopathy) were assessed using Cox proportional hazards regression models.
RESULTS
In total, 136 patients had microvascular complications at baseline. During a median follow-up of 3.2 years, 49 (34.5%) of 142 patients without microvascular complications at baseline developed new-onset microvascular complications. In multivariable Cox proportional hazards regression analyses, both total LDLP and HDLP concentrations, but not total TRLP concentrations, were positively associated with an increased risk of developing any microvascular complications after adjustment for potential confounding factors, including age, sex, disease duration, HbA1c levels, history of macrovascular complications, and statin use (adjusted hazard ratio [HR] per 1 SD increment: 1.70 [95% CI 1.24-2.34], P < 0.001 and 1.63 [95% CI 1.19-2.23], P = 0.002, respectively). When analyzing each microvascular complication individually, total LDLP concentrations were positively associated with retinopathy (adjusted HR 3.35, 95% CI 1.35-8.30, P = 0.009) and nephropathy (adjusted HR 2.13, 95% CI 1.27-3.35, P = 0.004), and total HDLP concentrations with neuropathy (adjusted HR 1.77, 95% CI 1.15-2.70, P = 0.009). No significant associations were observed for lipoprotein particle subfractions.
CONCLUSIONS
Total lipoprotein particle concentrations of both LDL and HDL associate positively with an increased risk of developing microvascular complications in T2D. We propose that the protective role of HDL on the development of microvascular complications may be lost in established T2D.

Identifiants

pubmed: 37415152
doi: 10.1186/s12933-023-01909-1
pii: 10.1186/s12933-023-01909-1
pmc: PMC10327395
doi:

Substances chimiques

Lipoproteins, HDL 0
Cholesterol, HDL 0
Lipoproteins 0
Lipoproteins, LDL 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

169

Informations de copyright

© 2023. The Author(s).

Références

Diabetes Care. 2015 Apr;38(4):628-36
pubmed: 25592196
Drugs. 2013 Mar;73(4):327-39
pubmed: 23479408
Lipids Health Dis. 2020 Dec 1;19(1):247
pubmed: 33261644
Circulation. 2005 Jun 28;111(25):3465-72
pubmed: 15983261
Int J Mol Sci. 2018 Jun 05;19(6):
pubmed: 29874886
Atherosclerosis. 2010 Aug;211(2):353-60
pubmed: 20189175
Diabetes Obes Metab. 2023 Aug;25(8):2374-2387
pubmed: 37202875
Clin Biochem. 2014 Nov;47(16-17):170-5
pubmed: 25149194
Semin Ophthalmol. 2016;31(1-2):10-8
pubmed: 26959124
Diabetologia. 2020 Jun;63(6):1248-1257
pubmed: 32152647
J Clin Endocrinol Metab. 2022 Aug 18;107(9):e3816-e3823
pubmed: 35647758
J Formos Med Assoc. 2020 Jan;119(1 Pt 1):51-58
pubmed: 30905491
Endocrine. 2023 May;80(2):312-316
pubmed: 36757630
BMJ. 1989 Feb 25;298(6672):487-90
pubmed: 2495077
Curr Opin Lipidol. 2011 Aug;22(4):254-61
pubmed: 21734572
J Clin Med. 2019 Sep 01;8(9):
pubmed: 31480611
Clin Biochem. 2014 Aug;47(12):1022-7
pubmed: 24769273
Arterioscler Thromb Vasc Biol. 2001 Apr;21(4):481-8
pubmed: 11304461
N Engl J Med. 2005 Jan 27;352(4):341-50
pubmed: 15673800
Clin Biochem. 1999 Mar;32(2):143-8
pubmed: 10211632
Curr Diab Rep. 2008 Feb;8(1):65-70
pubmed: 18367001
Diabetes Res Clin Pract. 2019 Nov;157:107843
pubmed: 31518657
J Am Soc Nephrol. 2014 Dec;25(12):2906-15
pubmed: 24854276
Circulation. 2014 Mar 4;129(9):999-1008
pubmed: 24352521
Cardiovasc Diabetol. 2017 Oct 12;16(1):132
pubmed: 29025405
N Engl J Med. 2014 Dec 18;371(25):2383-93
pubmed: 25404125
J Clin Lipidol. 2019 Jan - Feb;13(1):129-137.e1
pubmed: 30591414
Eur J Clin Invest. 2015 Jan;45(1):36-44
pubmed: 25402623
EClinicalMedicine. 2022 Jan 03;43:101261
pubmed: 35028547
J Intern Med. 2012 Dec;272(6):562-72
pubmed: 22650159
Diabetologia. 2003 Jun;46(6):733-49
pubmed: 12774165
Diabetes. 2003 Feb;52(2):453-62
pubmed: 12540621
J Clin Lipidol. 2020 Jan - Feb;14(1):122-132.e4
pubmed: 31791716
Diabetologia. 1989 Sep;32(9):685-9
pubmed: 2507381
Lipids Health Dis. 2019 Jan 18;18(1):18
pubmed: 30658647
Int J Mol Sci. 2019 Feb 23;20(4):
pubmed: 30813431
Circulation. 2020 Aug 18;142(7):657-669
pubmed: 32804568
Am J Med. 1993 Apr;94(4):350-6
pubmed: 8475928
Curr Opin Lipidol. 2021 Aug 1;32(4):249-257
pubmed: 34101657
J Intern Med. 2021 Jun;289(6):873-886
pubmed: 33283333
Nat Clin Pract Endocrinol Metab. 2006 Sep;2(9):504-11
pubmed: 16957764
Diabetes Metab Syndr Obes. 2022 Sep 28;15:3039-3048
pubmed: 36200065
Biomark Med. 2013 Jun;7(3):457-72
pubmed: 23734809
J Am Coll Cardiol. 2008 Feb 12;51(6):634-42
pubmed: 18261682
J Clin Endocrinol Metab. 2021 May 13;106(6):1761-1772
pubmed: 33567068
EBioMedicine. 2022 Nov;85:104292
pubmed: 36182774
Diabetes Res Clin Pract. 2009 Jan;83(1):132-9
pubmed: 19091436
Clin Biochem. 2014 Nov;47(16-17):203-10
pubmed: 25079243
Clin Lab Med. 2006 Dec;26(4):847-70
pubmed: 17110242
J Clin Lipidol. 2011 Sep-Oct;5(5):387-94
pubmed: 21981840
Eur J Clin Invest. 2010 Jun;40(6):483-9
pubmed: 20412290
J Am Heart Assoc. 2014 Mar 13;3(2):e000519
pubmed: 24627418
Circulation. 2021 May 18;143(20):1935-1945
pubmed: 33840204
Eur J Clin Invest. 2012 May;42(5):487-95
pubmed: 21955281
Cardiovasc Diabetol. 2021 Jul 28;20(1):156
pubmed: 34321006
Diabetologia. 2022 Feb;65(2):402-405
pubmed: 34800145
J Clin Med. 2019 Dec 03;8(12):
pubmed: 31817053

Auteurs

Arno R Bourgonje (AR)

Department of Gastroenterology and Hepatology, University of Groningen, University Medical Center Groningen, P.O. Box 30.001, 9700 RB, Groningen, The Netherlands. a.r.bourgonje@umcg.nl.
The Henry D. Janowitz Division of Gastroenterology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA. a.r.bourgonje@umcg.nl.

Margery A Connelly (MA)

Labcorp, Morrisville, NC, USA.

Harry van Goor (H)

Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.

Peter R van Dijk (PR)

Department of Internal Medicine, Division of Endocrinology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.

Robin P F Dullaart (RPF)

Department of Internal Medicine, Division of Endocrinology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH